Aripiprazole (Abilify) vs Aripiprazole (Abilify Maintena)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline
Aripiprazole (Abilify)
Marketed by Otsuka Holdings and partners
NCT00712686 · Phase 3 · completed
A randomised, double-blind, active-controlled trial of aripiprazole (n=355) against olanzapine (n=348) in acute schizophrenia, with two co-primary objectives. The published results are mixed: olanzapine was statistically superior on PANSS efficacy at week 6, so aripiprazole did not show non-inferiority, while aripiprazole caused significantly less weight gain at week 26. The registry has no posted results; the figures are from the publication (Fleischhacker et al., Biol Psychiatry 2009).
Next expected readout: July 2030 · NCT06969755 (registry estimate)
Reported efficacy
The mean change in the PANSS Total Score (from baseline to Week 6); The percentage of patients showing significant weight gain (a≥ 7% increase) (from baseline to Week 26): Mean change in PANSS Total Score from baseline to Week 6: aripiprazole -24.6 vs olanzapine -29.5 (random regression model); treatment difference 4.9 points, 95% CI 2.2-7.6, exceeding the pre-specified 6-point non-inferiority margin -- aripiprazole did not reach non-inferiority (olanzapine was statistically superior). Aripiprazole showed significantly less weight gain at Week 26: +0.13 kg vs +4.30 kg for olanzapine, and fewer patients with significant weight gain (21% vs 40%, p<.05). (mixed)
Result source: NCT00712686
Aripiprazole (Abilify Maintena)
Marketed by Otsuka Holdings and partners
NCT00706654 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial with 662 randomized maintenance-phase participants, including 265 assigned to depot 300/400 mg and 266 to oral aripiprazole. The primary clinical relapse endpoint was met: depot treatment was non-inferior to oral aripiprazole, with a difference of -0.64 percentage points and a 95% confidence interval of -5.26 to 3.99, below the prespecified 11.5% margin.
Reported efficacy
Mean change from baseline to endpoint(10th week)in PANSS Total Score. (1st,2nd,4th,6th,8th,10th,12th week): LS mean change from baseline to Week 10 in PANSS Total Score: -33.6 (aripiprazole once-monthly, AOM) vs -34.8 (oral aripiprazole); difference -1.2 (95% CI: -4.1, 1.7), within the pre-defined non-inferiority margin (met)
Result source: NCT03172871
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aripiprazole (Abilify) | Aripiprazole (Abilify Maintena) |
|---|---|---|
| PANSS total, change | -26.7 vs -21.2−5.5 vs placeboNCT0010206331 other results
| -26.8 vs -11.7−15.1 vs placeboNCT016635326 other results
|
| CGI-S, change | -1.2 vs -0.9−0.3 vs placeboNCT0010206332 other results
| -1.4 vs -0.6−0.8 vs placeboNCT016635326 other results
|
| PANSS response | —Not posted · NCT03485417 | 37% vs 14.3%+22.7 vs placeboNCT01663532 |
| PSP, change | —Not posted · NCT03485417 | 12.3 vs 5.2+7.1 vs placeboNCT01663532 |
| Relapse (% of patients) | 19.4% vs 37.5%−18.1 vs placeboNCT011496551 other result
| 10% vs 39.6%−29.6 vs placeboNCT00705783 |
PANSS total, change
- Aripiprazole (Abilify)
- -26.7 vs -21.2−5.5 vs placeboNCT00102063
31 other results
- -28.6 vs -21.2 NCT00102063
- -19.4 vs -22.9 NCT02054702
- -1.2 vs 3.9 NCT01149655
- -1.6 vs 3.7 NCT01149655
- -0.2 vs 4.5 NCT01149655
- -1.2 vs 2.9 NCT01149655
- -0.2 vs 5.5 NCT01149655
- -0.6 vs 1.6 NCT01149655
- -0.8 vs 5.6 NCT01149655
- -0.4 vs 1.8 NCT01149655
- 0.1 vs -0.6 NCT01149655
- -0.7 vs 5.6 NCT01149655
- 0.2 vs -0.3 NCT01149655
- -0.6 vs 6.1 NCT01149655
- -0.3 vs 6.1 NCT01149655
- -0.4 vs 5.9 NCT01149655
- -0.9 vs 5.8 NCT01149655
- -0.8 vs 5.7 NCT01149655
- -1.0 vs 5.6 NCT01149655
- -1.0 vs 6.2 NCT01149655
- -1.1 vs 5.8 NCT01149655
- -0.6 vs 5.4 NCT01149655
- -0.8 vs 5.2 NCT01149655
- -0.9 vs 5.1 NCT01149655
- -1.1 vs 4.9 NCT01149655
- -1.0 vs 4.9 NCT01149655
- -1.0 vs 4.8 NCT01149655
- -1.0 vs 4.7 NCT01149655
- -1.2 vs 4.7 NCT01149655
- -1.3 vs 4.8 NCT01149655
- -7.7 vs -9.3 NCT00216476
- Aripiprazole (Abilify Maintena)
- -26.8 vs -11.7−15.1 vs placeboNCT01663532
6 other results
- -23.7 vs -9.7 NCT01663532
- -21.5 vs -10.3 NCT01663532
- -19 vs -9.8 NCT01663532
- -15.2 vs -8.3 NCT01663532
- -8.9 vs -5 NCT01663532
- -33.6 vs -34.8 NCT03172871
CGI-S, change
- Aripiprazole (Abilify)
- -1.2 vs -0.9−0.3 vs placeboNCT00102063
32 other results
- -1.3 vs -0.9 NCT00102063
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.1 vs 0.4 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.4 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.3 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.2 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.1 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.1 NCT01149655
- 0.1 vs 0.3 NCT01149655
- 0.0 vs 0.1 NCT01149655
- 0 vs 0.0 NCT01149655
- 0.0 vs 0.0 NCT01149655
- -0.8 vs -0.5 NCT01795547
- -1.3 vs -1.6 NCT02054702
- -0.1 vs -0.3 NCT00216476
- Aripiprazole (Abilify Maintena)
- -1.4 vs -0.6−0.8 vs placeboNCT01663532
6 other results
- -1.3 vs -0.6 NCT01663532
- -1.2 vs -0.5 NCT01663532
- -1 vs -0.4 NCT01663532
- -0.8 vs -0.4 NCT01663532
- -0.4 vs -0.2 NCT01663532
- -0.8 vs -0.5 NCT01795547
PANSS response
- Aripiprazole (Abilify)
- —Not posted · NCT03485417
- Aripiprazole (Abilify Maintena)
- 37% vs 14.3%+22.7 vs placeboNCT01663532
PSP, change
- Aripiprazole (Abilify)
- —Not posted · NCT03485417
- Aripiprazole (Abilify Maintena)
- 12.3 vs 5.2+7.1 vs placeboNCT01663532
Relapse (% of patients)
- Aripiprazole (Abilify)
- 19.4% vs 37.5%−18.1 vs placeboNCT01149655
1 other result
- 10% vs 39.6% NCT00705783
- Aripiprazole (Abilify Maintena)
- 10% vs 39.6%−29.6 vs placeboNCT00705783
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
35 other shared endpoints and safety
Coverage. Aripiprazole (Abilify): 39 of 39 rows · Aripiprazole (Abilify Maintena): 39 of 39 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aripiprazole (Abilify) Rows use multiple source trials | Aripiprazole (Abilify Maintena) Rows use multiple source trials |
|---|---|---|
| All-cause Discontinuation responder rate · % of participants No placebo or comparator arm | 20.6% (n=1081) @ 52wk400/300 mg IM Depota,b NCT00731549 · Phase 3 · registry result, not featured evidence | 20.6% (n=1081) @ 52wk400/300 mg IM Depota,b NCT00731549 · Phase 3 · registry result, not featured evidence |
| CGI-I absolute value · score | 3.38 vs 3.9 placebo score @ 10wka,b NCT01149655 · Phase 3 · registry result, not featured evidence | 2.7 vs 3.7 placebo score @ 10wk400/300 mga,b NCT01663532 · Phase 3 |
| CGI-I absolute value · score Maintenance | 3.7 vs 4.53 placebo score @ 52wka,b NCT00705783 · Phase 3 · registry result, not featured evidence | 3.7 vs 4.53 placebo score @ 52wka,b NCT00705783 · Phase 3 · monotherapy |
| CGI-I absolute value · score No placebo or comparator arm | 3.25 score @ 52wk400/300 mg IM Depota,b NCT00731549 · Phase 3 · registry result, not featured evidence | 3.25 score @ 52wk400/300 mg IM Depota,b NCT00731549 · Phase 3 · registry result, not featured evidence |
| CGI-I absolute value · score No placebo or comparator arm Last visit (N=1079) | 3.35 score @ 52wk400/300 mg IM Depota,b Last visit (N=1079) NCT00731549 · Phase 3 · registry result, not featured evidence | 3.35 score @ 52wk400/300 mg IM Depota,b Last visit (N=1079) NCT00731549 · Phase 3 · registry result, not featured evidence |
| CGI-S absolute change · score Maintenance | 0.14 vs 0.66 placebo score @ 52wka,b NCT00705783 · Phase 3 · registry result, not featured evidence | 0.14 vs 0.66 placebo score @ 52wka,b NCT00705783 · Phase 3 · monotherapy |
| CGI-S absolute change · score No placebo or comparator arm | -0.3 score @ 52wka,b NCT01942148 · Phase 3 · registry result, not featured evidence 3 other source trials-0.24 score @ 52wk400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence 2.3 score @ 52wk10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 1.1 score @ 52wk5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence | -0.24 score @ 52wk400/300 mg IM Depota,b NCT00731549 · Phase 3 · registry result, not featured evidence |
| CGI-S absolute change · score No placebo or comparator arm Last visit (N=1079) | -0.14 score @ 52wk400/300 mg IM Depota,b Last visit (N=1079) NCT00731549 · Phase 3 · registry result, not featured evidence | -0.14 score @ 52wk400/300 mg IM Depota,b Last visit (N=1079) NCT00731549 · Phase 3 · registry result, not featured evidence |
| Clinical Remission responder rate · % of participants Maintenance | 52.9% (n=87) vs 38.7% (n=31) placebo @ 52wka,b NCT00705783 · Phase 3 · registry result, not featured evidence | 52.9% (n=87) vs 38.7% (n=31) placebo @ 52wka,b NCT00705783 · Phase 3 · monotherapy |
| Clinical Remission responder rate · % of participants No placebo or comparator arm | 48.8% (n=215) @ 38wk300 or 400 mgc,a,b NCT00706654 · Phase 3 · registry result, not featured evidence show 1 more dose59.7% (n=72) @ 38wk25 or 50 mg NCT00706654 · Phase 3 · registry result, not featured evidence | 48.8% (n=215) @ 38wk300 or 400 mgc,a,b NCT00706654 · Phase 3 show 1 more dose59.7% (n=72) @ 38wk25 or 50 mg NCT00706654 · Phase 3 |
| Exacerbation absolute value · percentage points No placebo or comparator arm | 7.12% (n=265) @ 26wk300 or 400 mgc,a,b NCT00706654 · Phase 3 · registry result, not featured evidence show 1 more dose21.8% (n=131) @ 26wk25 or 50 mg NCT00706654 · Phase 3 · registry result, not featured evidence | 7.12% (n=265) @ 26wk300 or 400 mgc,a,b NCT00706654 · Phase 3 show 1 more dose21.8% (n=131) @ 26wk25 or 50 mg NCT00706654 · Phase 3 |
| PANSS responder rate · % of participants Maintenance | 87.6% (n=267) vs 56% (n=134) placebo @ 52wka,b NCT00705783 · Phase 3 · registry result, not featured evidence | 87.6% (n=267) vs 56% (n=134) placebo @ 52wka,b NCT00705783 · Phase 3 · monotherapy |
| PANSS Negative absolute change · score No placebo or comparator arm | -0.96 score @ 4wk400mgc,a,b NCT01552772 · Phase 1 · registry result, not featured evidence show 1 more dose-0.92 score @ 4wk400mg NCT01552772 · Phase 1 · registry result, not featured evidence | -0.96 score @ 4wk400mgc,a,b NCT01552772 · Phase 1 · registry result, not featured evidence show 1 more dose-0.92 score @ 4wk400mg NCT01552772 · Phase 1 · registry result, not featured evidence |
| PANSS Negative Subscale absolute change · score | -0.33 vs 0.71 placebo score @ 10wka,b NCT01149655 · Phase 3 · registry result, not featured evidence | -4.5 vs -1.6 placebo score @ 10wk400/300 mga,b NCT01663532 · Phase 3 |
| PANSS Negative Subscale absolute change · score Maintenance | 0.19 vs 1.55 placebo score @ 52wka,b NCT00705783 · Phase 3 · registry result, not featured evidence | 0.19 vs 1.55 placebo score @ 52wka,b NCT00705783 · Phase 3 · monotherapy |
| PANSS Negative Subscale absolute change · score No placebo or comparator arm | -1.6 score @ 24wkd,a,b,e NCT01432444 · Phase 3 · registry result, not featured evidence | -0.33 score @ 20wk400 mgd,a,b,e NCT01909466 · Phase 1 · registry result, not featured evidence |
| PANSS Positive absolute change · score No placebo or comparator arm | -1.28 score @ 4wk400mgc,a,b NCT01552772 · Phase 1 · registry result, not featured evidence show 1 more dose-1.25 score @ 4wk400mg NCT01552772 · Phase 1 · registry result, not featured evidence | -1.28 score @ 4wk400mgc,a,b NCT01552772 · Phase 1 · registry result, not featured evidence show 1 more dose-1.25 score @ 4wk400mg NCT01552772 · Phase 1 · registry result, not featured evidence |
| PANSS Positive Subscale absolute change · score | -0.16 vs 1.63 placebo score @ 10wka,b NCT01149655 · Phase 3 · registry result, not featured evidence | -10 vs -4.9 placebo score @ 10wk400/300 mga,b NCT01663532 · Phase 3 |
| PANSS Positive Subscale absolute change · score Maintenance | 0.44 vs 4.25 placebo score @ 52wka,b NCT00705783 · Phase 3 · registry result, not featured evidence | 0.44 vs 4.25 placebo score @ 52wka,b NCT00705783 · Phase 3 · monotherapy |
| PANSS Positive Subscale absolute change · score No placebo or comparator arm | -3 score @ 24wkd,a,b,e NCT01432444 · Phase 3 · registry result, not featured evidence | -0.52 score @ 20wk400 mgd,a,b,e NCT01909466 · Phase 1 · registry result, not featured evidence |
| PANSS Total absolute change · score Maintenance | 1.43 vs 11.55 placebo score @ 52wka,b NCT00705783 · Phase 3 · registry result, not featured evidence | 1.43 vs 11.55 placebo score @ 52wka,b NCT00705783 · Phase 3 · monotherapy |
| PANSS Total absolute change · score No placebo or comparator arm | -7.9 score @ 52wka,b NCT01942148 · Phase 3 · registry result, not featured evidence 1 other source trial-3.55 score @ 52wk400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence | -3.55 score @ 52wk400/300 mg IM Depota,b NCT00731549 · Phase 3 · registry result, not featured evidence |
| PANSS Total absolute change · score No placebo or comparator arm Last visit (N=1078) | -1.72 score @ 52wk400/300 mg IM Depota,b Last visit (N=1078) NCT00731549 · Phase 3 · registry result, not featured evidence | -1.72 score @ 52wk400/300 mg IM Depota,b Last visit (N=1078) NCT00731549 · Phase 3 · registry result, not featured evidence |
| QLS Total absolute change · score | 7.47 vs 2.8 Paliperidone score @ 28wka,b NCT01795547 · Phase 3 · registry result, not featured evidence | 7.47 vs 2.8 Paliperidone score @ 28wka,b NCT01795547 · Phase 3 · registry result, not featured evidence |
| QLS Total absolute change · score No placebo or comparator arm | 2.32 score @ 24wka,b NCT01959035 · Phase 3 · registry result, not featured evidence | 2.32 score @ 24wka,b NCT01959035 · Phase 3 · registry result, not featured evidence |
| Relapse event count · % of participants No placebo or comparator arm | 0.3% (n=1081) @ 52wk400/300 mg IM Depotc,a,b NCT00731549 · Phase 3 · registry result, not featured evidence show 1 more dose8.2% (n=1079) @ 52wk400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence | 0.3% (n=1081) @ 52wk400/300 mg IM Depotc,a,b NCT00731549 · Phase 3 · registry result, not featured evidence show 1 more dose8.2% (n=1079) @ 52wk400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence |
| Relapse Free responder rate · % of participants No placebo or comparator arm | 98.96% (n=1081) @ 52wk400/300 mg IM Depota,b NCT00731549 · Phase 3 · registry result, not featured evidence | 98.96% (n=1081) @ 52wk400/300 mg IM Depota,b NCT00731549 · Phase 3 · registry result, not featured evidence |
| Relapse Free responder rate · % of participants No placebo or comparator arm Last visit (N=1072) | 94.96% (n=1081) @ 52wk400/300 mg IM Depota,b Last visit (N=1072) NCT00731549 · Phase 3 · registry result, not featured evidence | 94.96% (n=1081) @ 52wk400/300 mg IM Depota,b Last visit (N=1072) NCT00731549 · Phase 3 · registry result, not featured evidence |
| Relapse Occurrence responder rate · % of participants No placebo or comparator arm Overall (N=1079) | 8.25% (n=1081) @ 52wk400/300 mg IM Depota,b Overall (N=1079) NCT00731549 · Phase 3 · registry result, not featured evidence | 8.25% (n=1081) @ 52wk400/300 mg IM Depota,b Overall (N=1079) NCT00731549 · Phase 3 · registry result, not featured evidence |
| Remission responder rate · % of participants No placebo or comparator arm | 51.7% (n=1081) @ 52wk400/300 mg IM Depota,b NCT00731549 · Phase 3 · registry result, not featured evidence | 51.7% (n=1081) @ 52wk400/300 mg IM Depota,b NCT00731549 · Phase 3 · registry result, not featured evidence |
| Responder responder rate · % of participants No placebo or comparator arm | 89.8% (n=264) @ 38wk300 or 400 mgc,a,b NCT00706654 · Phase 3 · registry result, not featured evidence show 1 more dose75.2% (n=129) @ 38wk25 or 50 mg NCT00706654 · Phase 3 · registry result, not featured evidence | 89.8% (n=264) @ 38wk300 or 400 mgc,a,b NCT00706654 · Phase 3 show 1 more dose75.2% (n=129) @ 38wk25 or 50 mg NCT00706654 · Phase 3 |
| SWN-K Total absolute change · score | 4.82 vs 3.81 Paliperidone score @ 28wka,b NCT01795547 · Phase 3 · registry result, not featured evidence | 4.82 vs 3.81 Paliperidone score @ 28wka,b NCT01795547 · Phase 3 · registry result, not featured evidence |
| SWN-K Total absolute change · score No placebo or comparator arm | 0.19 score @ 24wka,b NCT01959035 · Phase 3 · registry result, not featured evidence | 0.19 score @ 24wka,b NCT01959035 · Phase 3 · registry result, not featured evidence |
| Time to Exacerbation time to event · months Maintenance | NA vs 6.87 placebo months @ 52wka,b NCT00705783 · Phase 3 · registry result, not featured evidence | NA vs 6.87 placebo months @ 52wka,b NCT00705783 · Phase 3 · monotherapy |
| Time to Exacerbation time to event · months No placebo or comparator arm | NA months300 or 400 mgc,a,b,f NCT00706654 · Phase 3 · registry result, not featured evidence show 1 more doseNA months25 or 50 mg NCT00706654 · Phase 3 · registry result, not featured evidence | NA months300 or 400 mgc,a,b,f NCT00706654 · Phase 3 show 1 more doseNA months25 or 50 mg NCT00706654 · Phase 3 |
| Dropout rate | 20%g NCT00345033 · Phase 4 · registry result, not featured evidence show 30 more results39.7% NCT01942148 · Phase 3 · registry result, not featured evidence 12.5% NCT01959035 · Phase 3 · registry result, not featured evidence 32.4% NCT01795547 · Phase 3 · registry result, not featured evidence 36.4% NCT02054702 · Phase 3 · registry result, not featured evidence — NCT01149655 · Phase 3 · registry result, not featured evidence — NCT01432444 · Phase 3 · registry result, not featured evidence 20.6%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence 40.2%10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 45%5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —300 or 400 mg NCT00706654 · Phase 3 · registry result, not featured evidence —25 or 50 mg NCT00706654 · Phase 3 · registry result, not featured evidence 84.7% NCT01001702 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot NCT00705783 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · registry result, not featured evidence 37.8% NCT00216476 · Phase 3 · registry result, not featured evidence 26.8% NCT00102518 · Phase 3 · registry result, not featured evidence 16%10 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 17.6%30 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 14.6%24-30 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 20%6-12 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 22.9%2 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 11.1%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 26.3%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 6.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence 0%30 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0%20 mg NCT00102479 · Phase 1 · registry result, not featured evidence 16.7% NCT01338298 · Phase na · registry result, not featured evidence | —300 or 400 mgg NCT00706654 · Phase 3 show 13 more results—25 or 50 mg NCT00706654 · Phase 3 —Aripiprazole Depot NCT00705783 · Phase 3 · monotherapy —Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · monotherapy 44%400/300 mg NCT01663532 · Phase 3 26.1% NCT02360319 · Phase 4 · registry result, not featured evidence 12.5% NCT01959035 · Phase 3 · registry result, not featured evidence 32.4% NCT01795547 · Phase 3 · registry result, not featured evidence 39.2%400/300 mg NCT01683058 · Phase 3 · registry result, not featured evidence 20.6%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence —400 mg NCT01909466 · Phase 1 · registry result, not featured evidence 11.1%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 26.3%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 6.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —g NCT00345033 · Phase 4 · registry result, not featured evidence show 30 more results5.9% NCT01942148 · Phase 3 · registry result, not featured evidence 5.7% NCT01959035 · Phase 3 · registry result, not featured evidence 10.8% NCT01795547 · Phase 3 · registry result, not featured evidence 3% NCT02054702 · Phase 3 · registry result, not featured evidence — NCT01149655 · Phase 3 · registry result, not featured evidence — NCT01432444 · Phase 3 · registry result, not featured evidence 2.9%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence 6.2%10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 0%5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —300 or 400 mg NCT00706654 · Phase 3 · registry result, not featured evidence —25 or 50 mg NCT00706654 · Phase 3 · registry result, not featured evidence 8.2% NCT01001702 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot NCT00705783 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · registry result, not featured evidence 2.2% NCT00216476 · Phase 3 · registry result, not featured evidence — NCT00102518 · Phase 3 · registry result, not featured evidence 7%10 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 3.9%30 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 12.2%24-30 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 6.7%6-12 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 2.9%2 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence —400 mg NCT01646827 · Phase 1 · registry result, not featured evidence —400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 1.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence —30 mg NCT00102479 · Phase 1 · registry result, not featured evidence —25 mg NCT00102479 · Phase 1 · registry result, not featured evidence —20 mg NCT00102479 · Phase 1 · registry result, not featured evidence — NCT01338298 · Phase na · registry result, not featured evidence | —300 or 400 mgg NCT00706654 · Phase 3 show 13 more results—25 or 50 mg NCT00706654 · Phase 3 —Aripiprazole Depot NCT00705783 · Phase 3 · monotherapy —Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · monotherapy 4.2%400/300 mg NCT01663532 · Phase 3 — NCT02360319 · Phase 4 · registry result, not featured evidence 5.7% NCT01959035 · Phase 3 · registry result, not featured evidence 10.8% NCT01795547 · Phase 3 · registry result, not featured evidence 8.1%400/300 mg NCT01683058 · Phase 3 · registry result, not featured evidence 2.9%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence —400 mg NCT01909466 · Phase 1 · registry result, not featured evidence —400 mg NCT01646827 · Phase 1 · registry result, not featured evidence —400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 1.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 0%g NCT00345033 · Phase 4 · registry result, not featured evidence show 30 more results10.3% NCT01942148 · Phase 3 · registry result, not featured evidence 3.4% NCT01959035 · Phase 3 · registry result, not featured evidence 8.3% NCT01795547 · Phase 3 · registry result, not featured evidence 3% NCT02054702 · Phase 3 · registry result, not featured evidence 3.1% NCT01149655 · Phase 3 · registry result, not featured evidence 14.2% NCT01432444 · Phase 3 · registry result, not featured evidence 8.8%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence —10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence —5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 0%5 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 13.4%10 - 30 mg QD NCT00239356 · Phase 3 · registry result, not featured evidence 5.7%300 or 400 mg NCT00706654 · Phase 3 · registry result, not featured evidence 8.4%25 or 50 mg NCT00706654 · Phase 3 · registry result, not featured evidence 12.9% NCT01001702 · Phase 3 · registry result, not featured evidence —Aripiprazole Depot NCT00705783 · Phase 3 · registry result, not featured evidence 4.1%Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · registry result, not featured evidence 15.6% NCT00216476 · Phase 3 · registry result, not featured evidence 6.2% NCT00102518 · Phase 3 · registry result, not featured evidence 4%10 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 3.9%30 mg/day NCT00102063 · Phase 3 · registry result, not featured evidence 4.9%24-30 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 6.7%6-12 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 0%2 mg/day NCT01942161 · Phase 2/3 · registry result, not featured evidence 0%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 0%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 1.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence 0%30 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0%20 mg NCT00102479 · Phase 1 · registry result, not featured evidence 0% NCT01338298 · Phase na · registry result, not featured evidence | 5.7%300 or 400 mgg NCT00706654 · Phase 3 show 13 more results8.4%25 or 50 mg NCT00706654 · Phase 3 —Aripiprazole Depot NCT00705783 · Phase 3 · monotherapy 4.1%Aripiprazole Depot - Depot Mainten NCT00705783 · Phase 3 · monotherapy 4.8%400/300 mg NCT01663532 · Phase 3 29.1% NCT02360319 · Phase 4 · registry result, not featured evidence 3.4% NCT01959035 · Phase 3 · registry result, not featured evidence 8.3% NCT01795547 · Phase 3 · registry result, not featured evidence 6.8%400/300 mg NCT01683058 · Phase 3 · registry result, not featured evidence 8.8%400/300 mg IM Depot NCT00731549 · Phase 3 · registry result, not featured evidence 2.9%400 mg NCT01909466 · Phase 1 · registry result, not featured evidence 0%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 0%400 mg NCT01646827 · Phase 1 · registry result, not featured evidence 1.7%400mg NCT01552772 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | g eye irritation/swelling 6.3% (placebo 0%) psychiatric decompensation 6.3% (placebo 0%) psychiatric decompensation 6.3% (placebo 0%) NCT00345033 · Phase 4 · registry result, not featured evidence show 27 more resultsnasopharyngitis 45.6% somnolence 20.6% nausea 17.6% NCT01942148 · Phase 3 · registry result, not featured evidence weight increased 6.8% NCT01959035 · Phase 3 · registry result, not featured evidence accidental overdose 20.8% insomnia 11.8% weight increased 9% NCT01795547 · Phase 3 · registry result, not featured evidence akathisia 21.2% headache 12.1% constipation 9.1% NCT02054702 · Phase 3 · registry result, not featured evidence schizophrenia 9.2% (placebo 16.7%) weight increased 8.2% (placebo 10.4%) nasopharyngitis 7.1% (placebo 2.1%) NCT01149655 · Phase 3 · registry result, not featured evidence insomnia 6.7% akathisia 6.3% weight increased 2.3% NCT01432444 · Phase 3 · registry result, not featured evidence 400/300 mg IM Depot headache 7.6% nasopharyngitis 7% anxiety 6.8% NCT00731549 · Phase 3 · registry result, not featured evidence 5 - 30 mg QD pyrexia 35% headache 30% cough 15% NCT00239356 · Phase 3 · registry result, not featured evidence 10 - 30 mg QD back pain 7.2% anxiety 6.2% headache 6.2% NCT00239356 · Phase 3 · registry result, not featured evidence 300 or 400 mg insomnia 11.7% akathisia 10.6% headache 9.8% NCT00706654 · Phase 3 · registry result, not featured evidence 25 or 50 mg insomnia 13.7% back pain 11.5% weight decreased 9.2% NCT00706654 · Phase 3 · registry result, not featured evidence headache 15.3% influenza 10.6% weight increased 10.6% NCT01001702 · Phase 3 · registry result, not featured evidence insomnia 10% (placebo 9%) weight increased 9.7% (placebo 9.7%) anxiety 5.9% (placebo 7.5%) NCT00705783 · Phase 3 · registry result, not featured evidence insomnia 24.4% anxiety 15.6% headache 11.1% NCT00216476 · Phase 3 · registry result, not featured evidence extrapyramidal disorder 14.8% somnolence 12.9% headache 9.5% NCT00102518 · Phase 3 · registry result, not featured evidence 10 mg/day headache 16% (placebo 10%) extrapyramidal disorder 13% (placebo 5%) insomnia 11% (placebo 15%) NCT00102063 · Phase 3 · registry result, not featured evidence 30 mg/day extrapyramidal disorder 21.6% (placebo 5%) somnolence 21.6% (placebo 6%) tremor 11.8% (placebo 2%) NCT00102063 · Phase 3 · registry result, not featured evidence 24-30 mg/day nausea 22% insomnia 17.1% salivary hypersecretion 14.6% NCT01942161 · Phase 2/3 · registry result, not featured evidence 6-12 mg/day insomnia 20% somnolence 20% epistaxis 13.3% NCT01942161 · Phase 2/3 · registry result, not featured evidence 2 mg/day nausea 20% insomnia 14.3% nasopharyngitis 14.3% NCT01942161 · Phase 2/3 · registry result, not featured evidence 400 mg injection site pain 35.3% headache 23.5% akathisia 17.6% NCT01646827 · Phase 1 · registry result, not featured evidence 400 mg injection site pain 27.8% headache 22.2% akathisia 16.7% NCT01646827 · Phase 1 · registry result, not featured evidence 400mg injection site pain 6.7% toothache 6.7% blood creatine phosphokinase increased 5% NCT01552772 · Phase 1 · registry result, not featured evidence 30 mg headache 50% sedation 33.3% abdominal pain upper 16.7% NCT00102479 · Phase 1 · registry result, not featured evidence 25 mg abdominal pain upper 42.9% acne 28.6% dizziness 28.6% NCT00102479 · Phase 1 · registry result, not featured evidence 20 mg headache 50% insomnia 25% musculoskeletal stiffness 25% NCT00102479 · Phase 1 · registry result, not featured evidence nausea 50% (placebo 22.2%) vomiting 50% (placebo 38.9%) diarrhea 45% (placebo 38.9%) NCT01338298 · Phase na · registry result, not featured evidence | show 12 more resultsinsomnia 10% (placebo 9%) weight increased 9.7% (placebo 9.7%) anxiety 5.9% (placebo 7.5%) NCT00705783 · Phase 3 · monotherapy 400/300 mg weight increased 16.8% (placebo 7%) headache 14.4% (placebo 16.3%) akathisia 11.4% (placebo 3.5%) NCT01663532 · Phase 3 weight gain 14.4% anxiety 12.2% depression 10.4% NCT02360319 · Phase 4 · registry result, not featured evidence weight increased 6.8% NCT01959035 · Phase 3 · registry result, not featured evidence accidental overdose 20.8% insomnia 11.8% weight increased 9% NCT01795547 · Phase 3 · registry result, not featured evidence 400/300 mg weight increased 29.7% akathisia 12.2% headache 8.1% NCT01683058 · Phase 3 · registry result, not featured evidence 400/300 mg IM Depot headache 7.6% nasopharyngitis 7% anxiety 6.8% NCT00731549 · Phase 3 · registry result, not featured evidence 400 mg injection site pain 27.5% weight increased 12.3% headache 11.6% NCT01909466 · Phase 1 · registry result, not featured evidence 400 mg injection site pain 35.3% headache 23.5% akathisia 17.6% NCT01646827 · Phase 1 · registry result, not featured evidence 400 mg injection site pain 27.8% headache 22.2% akathisia 16.7% NCT01646827 · Phase 1 · registry result, not featured evidence 400mg injection site pain 6.7% toothache 6.7% blood creatine phosphokinase increased 5% NCT01552772 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dTrial phases differ: Phase 3 versus Phase 1.
- eAssessment timepoints differ: 24 weeks versus 20 weeks.
- fThe assessment timepoint is not available for both results.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aripiprazole (Abilify)
show 3 more results
show 1 more result
+ 16 further endpoints in the CSV export.
Aripiprazole (Abilify Maintena)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify)'s landscape · Aripiprazole (Abilify Maintena)'s landscape